For instance, long‐chain acylcarnitine have been proposed as potential biomarkers for IS,[5] while the methylation status of the MGMT promoter has been linked to distinct lipid metabolism patterns in glioblastoma.[179] Moreover, the expression of LDAPs, such as AUP1,[177] has been correlated with glioblastoma proliferation and neuroinflammation. Here, MGMT is linked to glioblastoma.